Announcing our newest cancer test. Screen cancer early with Onco-D-clare. Learn more
The number of new cancer cases diagnosed each year is staggering. In 2024, there will be an estimated 2 million new cases of cancer in the United States. Early detection is crucial, as it can significantly increase survival rates and improve treatment outcomes.
Blood tests can be a powerful ally in this fight against cancer. By providing valuable information about a person's health and potentially identifying early signs of the disease, blood tests can empower patients and doctors to take timely action. This can lead to earlier intervention, potentially less aggressive treatment options with fewer side effects, and ultimately, a better chance of successful treatment and a longer, healthier life.
A Complete Blood Count (CBC) is a common blood test that provides valuable information about a person's overall health, including red blood cell count, white blood cell count, and platelet levels. However, while CBCs play a vital role in routine health checks, their ability to detect cancer early is often limited. Abnormal results might not show up until later stages of the disease.
At RGCC, we believe in empowering patients with advanced tools for early cancer detection. Our liquid biopsies are innovative and advanced blood tests that offer a more precise and sensitive approach to potentially identify cancer at its earliest stages, even before traditional methods show any abnormalities.
Liquid biopsies analyze blood samples for:
By detecting these markers, liquid biopsies can provide valuable insights into potential cancer development, even before traditional methods show abnormalities.
Watch this video to learn more about RGCC’s liquid biopsies from our founder, Dr. Ioannis Papasotiriou.
A liquid biopsy is a relatively simple outpatient procedure. Here's what to expect:
Our liquid biopsies are a minimally invasive approach to potentially identify cancer at its earliest stages. They offer several additional advantages over traditional methods:
At RGCC, we are at the forefront of developing and using advanced liquid biopsy tests. Our range of tests offers a comprehensive approach to early cancer detection.
The Onco-D-clare test analyzes gene expression patterns in your blood sample and offers the potential for early detection of various cancers even before symptoms arise. Early cancer detection allows for proactive management, increasing the chances of successful intervention and treatment.
Our Onconomics panels are blood tests that provide deeper insight into the possible treatment options that are likely to work best on your cancer. This personalized approach helps guide treatment decisions by identifying the most effective anti-cancer drugs, targeted therapies, or even natural substances for a patient's specific cancer.
Our CTC tests analyze blood samples to detect the presence and concentration of circulating tumor cells (CTCs). They are valuable for monitoring a patient's response to treatment and potentially identifying early signs of relapse.
These tests can be particularly valuable for individuals with:
Early detection is key in the fight against cancer. Discuss the possibility of advanced blood tests, like liquid biopsies, with your RGCC registered practitioner to see if they might be right for you. They can help you understand your individual risk factors and determine the best course of action for early detection and preventative measures.
By working collaboratively with your doctor and exploring the possibilities offered by our advanced blood tests, you can empower yourself with a more comprehensive understanding of your cancer and take a proactive approach to your diagnosis and treatment journey.
Discover groundbreaking cancer testing solutions pioneered by RGCC, which throw light on the path toward better cancer care. We offer a paradigm shift in cancer care technologies and protocols.
Get in touch today to start your journey to empowering information for your cancer treatment by contacting us online.
Explore our curated collection of videos, providing an in-depth look at our innovative solutions and groundbreaking research.
In this insightful interview from the 2023 RGCC Gathering, Dr. Clayton Bell shares his journey of integrating RGCC technologies into his practice in the U.S.
With a background in Functional, Environmental, and Integrative Medicine, Dr. Bell reveals how he uses RGCC’s cutting-edge cancer diagnostics and therapies to support his patients’ healing. Watch the full video to learn more.
Helena Pöhlmann who specializes in holistic medicine shares how she utilizes RGCC products in her clinic to best support her patients. Watch the video to learn about her experience at the 2023 RGCC Gathering in Switzerland.
Cancer survivor and RGCC Practitioner, Jenny Hrbaceck, discusses RGCC testing and the impact it has made on her life.
Watch an interview with Dr. Bita Badakhshan, a seasoned practitioner in primary family medicine with over 12 years of experience in integrative oncology and functional medicine.
In this video, Dr. Bita shares her experience with RGCC’s transformative liquid biopsy testing. She highlights the unparalleled precision and detail offered by RGCC's advanced methodologies over other laboratories.
Dr. Bita emphasizes the unmatched sensitivity of RGCC's testing, which delves deep into analyzing stem cells, cancer cells, and a comprehensive array of markers crucial for personalized cancer care.
Since 2012, Dr. Beta has trusted RGCC for blood testing on patients, particularly focusing on circulating tumor cell analysis and using RGCC’s Oncocount and Oncotrace tests along with the Onconomics Plus assessments.
Through RGCC's innovative tests and therapies, Dr. Bita has been able to make informed decisions sparing many patients from unnecessary chemotherapy and radiation post-tumor removal surgeries.
Join host Sam Tejada for an essential conversation about cancer innovation and breakthroughs on this episode of A Healthy Point of View, including a close look at advances in early cancer detection - as early as stage ZERO.
Tejada sits down with two leading medical experts: Dr. Christopher Davis, an interventional cardiologist and CMO of Liquivida, and Dr. Ioannis Papasotiriou, MD, PhD, SCym, the founder of RGCC.
Together, they tackle one of medicine's most complex challenges, sharing cutting-edge insights and breakthrough approaches that could transform how we understand and address cancer care.
Explore our curated collection of videos, providing an in-depth look at our innovative solutions and groundbreaking research.
In this insightful interview from the 2023 RGCC Gathering, Dr. Clayton Bell shares his journey of integrating RGCC technologies into his practice in the U.S.
With a background in Functional, Environmental, and Integrative Medicine, Dr. Bell reveals how he uses RGCC’s cutting-edge cancer diagnostics and therapies to support his patients’ healing. Watch the full video to learn more.
Helena Pöhlmann who specializes in holistic medicine shares how she utilizes RGCC products in her clinic to best support her patients. Watch the video to learn about her experience at the 2023 RGCC Gathering in Switzerland.
Cancer survivor and RGCC Practitioner, Jenny Hrbaceck, discusses RGCC testing and the impact it has made on her life.
Watch an interview with Dr. Bita Badakhshan, a seasoned practitioner in primary family medicine with over 12 years of experience in integrative oncology and functional medicine.
In this video, Dr. Bita shares her experience with RGCC’s transformative liquid biopsy testing. She highlights the unparalleled precision and detail offered by RGCC's advanced methodologies over other laboratories.
Dr. Bita emphasizes the unmatched sensitivity of RGCC's testing, which delves deep into analyzing stem cells, cancer cells, and a comprehensive array of markers crucial for personalized cancer care.
Since 2012, Dr. Beta has trusted RGCC for blood testing on patients, particularly focusing on circulating tumor cell analysis and using RGCC’s OncoCount and OncoTrace tests along with the Onconomics Plus assessments.
Through RGCC's innovative tests and therapies, Dr. Bita has been able to make informed decisions sparing many patients from unnecessary chemotherapy and radiation post-tumor removal surgeries.
Read more about our therapies on our website: https://rgcc-international.com/rgcc-therapies/
RGCC was launched in 2004 by genetics pioneer Dr. Ioannis Papasotiriou who believes that the key to effectively treating cancer lies in personalized medicine using the information in a patient’s genes.
Individualized treatment for cancer is the focus behind RGCC’s testing protocols and advanced therapy options. Our slate of tests analyzes the state of a person’s cancer by looking at the cellular and genetic makeup of each patient. Our test results give you information that acts as a blueprint for what treatment protocols are likely to show the most efficacy for your specific biology.
Learn more about RGCC at
https://rgcc-international.com/
Follow us on social media to find out the latest news and updates from our experts.
Facebook: https://www.facebook.com/profile.php?id=61554630098937
Instagram: https://www.instagram.com/rgcc_north_america/
LinkedIn: https://www.linkedin.com/company/r-g-c-c-international-gmbh/
Join host Sam Tejada for an essential conversation about cancer innovation and breakthroughs on this episode of A Healthy Point of View, including a close look at advances in early cancer detection - as early as stage ZERO.
Tejada sits down with two leading medical experts: Dr. Christopher Davis, an interventional cardiologist and CMO of Liquivida, and Dr. Ioannis Papasotiriou, MD, PhD, SCym, the founder of RGCC.
Together, they tackle one of medicine's most complex challenges, sharing cutting-edge insights and breakthrough approaches that could transform how we understand and address cancer care.
